IDEXX LABORATORIES INC (IDXX) Stock Fundamental Analysis
NASDAQ:IDXX • US45168D1046
623.13 USD
-12.53 (-1.97%)
At close: Feb 23, 2026
623.13 USD
0 (0%)
After Hours: 2/23/2026, 8:00:02 PM
Overall IDXX gets a fundamental rating of 7 out of 10. We evaluated IDXX against 185 industry peers in the Health Care Equipment & Supplies industry. IDXX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IDXX is not valued too expensively and it also shows a decent growth rate. These ratings would make IDXX suitable for quality investing!
1. Profitability
1.1 Basic Checks
- IDXX had positive earnings in the past year.
- IDXX had a positive operating cash flow in the past year.
- In the past 5 years IDXX has always been profitable.
- IDXX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 30.34%, IDXX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 65.81%, IDXX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- IDXX has a Return On Invested Capital of 40.35%. This is amongst the best in the industry. IDXX outperforms 100.00% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for IDXX is significantly above the industry average of 8.75%.
- The last Return On Invested Capital (40.35%) for IDXX is above the 3 year average (37.60%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.35% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
1.3 Margins
- The Profit Margin of IDXX (24.65%) is better than 95.68% of its industry peers.
- In the last couple of years the Profit Margin of IDXX has grown nicely.
- IDXX has a better Operating Margin (31.34%) than 98.92% of its industry peers.
- In the last couple of years the Operating Margin of IDXX has grown nicely.
- The Gross Margin of IDXX (61.72%) is better than 64.86% of its industry peers.
- In the last couple of years the Gross Margin of IDXX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
- IDXX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for IDXX has been reduced compared to 1 year ago.
- The number of shares outstanding for IDXX has been reduced compared to 5 years ago.
- IDXX has a better debt/assets ratio than last year.
2.2 Solvency
- IDXX has an Altman-Z score of 21.48. This indicates that IDXX is financially healthy and has little risk of bankruptcy at the moment.
- IDXX has a better Altman-Z score (21.48) than 96.22% of its industry peers.
- IDXX has a debt to FCF ratio of 1.04. This is a very positive value and a sign of high solvency as it would only need 1.04 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 1.04, IDXX belongs to the best of the industry, outperforming 90.27% of the companies in the same industry.
- A Debt/Equity ratio of 0.53 indicates that IDXX is somewhat dependend on debt financing.
- IDXX has a Debt to Equity ratio of 0.53. This is comparable to the rest of the industry: IDXX outperforms 40.54% of its industry peers.
- Even though the debt/equity ratio score it not favorable for IDXX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 21.48 |
ROIC/WACC4.08
WACC9.89%
2.3 Liquidity
- IDXX has a Current Ratio of 1.18. This is a normal value and indicates that IDXX is financially healthy and should not expect problems in meeting its short term obligations.
- IDXX has a worse Current ratio (1.18) than 82.16% of its industry peers.
- IDXX has a Quick Ratio of 1.18. This is a bad value and indicates that IDXX is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Quick ratio value of 0.87, IDXX is not doing good in the industry: 81.62% of the companies in the same industry are doing better.
- IDXX does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 16.18% over the past year.
- Measured over the past years, IDXX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.26% on average per year.
- Looking at the last year, IDXX shows a quite strong growth in Revenue. The Revenue has grown by 10.42% in the last year.
- The Revenue has been growing by 9.72% on average over the past years. This is quite good.
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
3.2 Future
- IDXX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.75% yearly.
- IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.46% yearly.
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue Next Year9.11%
Revenue Next 2Y8.86%
Revenue Next 3Y8.98%
Revenue Next 5Y9.46%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- IDXX is valuated quite expensively with a Price/Earnings ratio of 47.68.
- Based on the Price/Earnings ratio, IDXX is valued a bit cheaper than 69.73% of the companies in the same industry.
- IDXX is valuated expensively when we compare the Price/Earnings ratio to 26.64, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 42.06 indicates a quite expensive valuation of IDXX.
- IDXX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. IDXX is cheaper than 68.11% of the companies in the same industry.
- IDXX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.75.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.68 | ||
| Fwd PE | 42.06 |
4.2 Price Multiples
- 68.11% of the companies in the same industry are more expensive than IDXX, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than the industry average as 72.43% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 52.92 | ||
| EV/EBITDA | 34.62 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The excellent profitability rating of IDXX may justify a higher PE ratio.
- A more expensive valuation may be justified as IDXX's earnings are expected to grow with 13.30% in the coming years.
PEG (NY)3.57
PEG (5Y)3.34
EPS Next 2Y13.1%
EPS Next 3Y13.3%
5. Dividend
5.1 Amount
- IDXX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
623.13
-12.53 (-1.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-02 2026-02-02/bmo
Earnings (Next)04-29 2026-04-29/bmo
Inst Owners94.94%
Inst Owner Change11.39%
Ins Owners0.21%
Ins Owner Change2.75%
Market Cap49.76B
Revenue(TTM)4.30B
Net Income(TTM)1.03B
Analysts80.91
Price Target781.34 (25.39%)
Short Float %2.29%
Short Ratio3.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)-0.28%
PT rev (3m)1.06%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)0.06%
EPS NY rev (1m)0.19%
EPS NY rev (3m)2.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.36%
Revenue NY rev (3m)2.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.68 | ||
| Fwd PE | 42.06 | ||
| P/S | 11.94 | ||
| P/FCF | 52.92 | ||
| P/OCF | 45.73 | ||
| P/B | 31.87 | ||
| P/tB | 48.18 | ||
| EV/EBITDA | 34.62 |
EPS(TTM)13.07
EY2.1%
EPS(NY)14.82
Fwd EY2.38%
FCF(TTM)11.77
FCFY1.89%
OCF(TTM)13.63
OCFY2.19%
SpS52.19
BVpS19.55
TBVpS12.93
PEG (NY)3.57
PEG (5Y)3.34
Graham Number75.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.35% | ||
| ROICexc | 43.87% | ||
| ROICexgc | 56.38% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
ROICexc(3y)42.72%
ROICexc(5y)42.26%
ROICexgc(3y)50.78%
ROICexgc(5y)53.04%
ROCE(3y)53.41%
ROCE(5y)55.15%
ROICexgc growth 3Y-1.85%
ROICexgc growth 5Y-3.56%
ROICexc growth 3Y7.2%
ROICexc growth 5Y1.43%
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 21.48 |
F-Score8
WACC9.89%
ROIC/WACC4.08
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.3%
Cap/Sales(5y)3.67%
Profit Quality(3y)93.71%
Profit Quality(5y)84.62%
High Growth Momentum
Growth
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
Revenue Next Year9.11%
Revenue Next 2Y8.86%
Revenue Next 3Y8.98%
Revenue Next 5Y9.46%
EBIT growth 1Y17.46%
EBIT growth 3Y14.66%
EBIT growth 5Y14.37%
EBIT Next Year22.21%
EBIT Next 3Y14.34%
EBIT Next 5Y15.18%
FCF growth 1Y18.62%
FCF growth 3Y40.13%
FCF growth 5Y14.37%
OCF growth 1Y18.68%
OCF growth 3Y29.59%
OCF growth 5Y12.77%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
What is the valuation status of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What are the PE and PB ratios of IDEXX LABORATORIES INC (IDXX) stock?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 47.68 and the Price/Book (PB) ratio is 31.87.
What is the expected EPS growth for IDEXX LABORATORIES INC (IDXX) stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 13.36% in the next year.